Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) (CHALLAH)

This study has been completed.
Sponsor:
Collaborators:
Texas Children's Hospital
The Methodist Hospital System
Brigham and Women's Hospital
Massachusetts General Hospital
M.D. Anderson Cancer Center
National Marrow Donor Program
The EMMES Corporation
Duke University
Beth Israel Deaconess Medical Center
Children's Hospital Los Angeles
National Heart, Lung, and Blood Institute (NHLBI)
Boston Children’s Hospital
University of Miami
Hackensack University Medical Center
University of California, Los Angeles
Information provided by (Responsible Party):
Helen Heslop, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00711035
First received: June 20, 2008
Last updated: March 25, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2013
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: March 3, 2014
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):